YOLFTbeta
Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings Inc

MTNB · AMEX · Healthcare / Biotechnology

0.90USD-0.02 (-2.00%)

Price History

Full chart

Market Stats

Previous Close0.9184
Open0.90
Day Range0.87 – 0.90
52-Week Range0.0102 – 2.65
Volume43.21K
Market Cap156.72K
P/E (TTM)0.00
Forward P/E0.00
EPS-1.15
Dividend Yield0.00%
Beta1.70
50-Day Avg0.2306
200-Day Avg0.5382

About

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jerome D. Jabbour J.D.
  • Employees2
  • Headquarters1545 Route 206 South, Bedminster, NJ, United States, 07921, USA
  • Websitehttps://www.matinasbiopharma.com

Leadership

  • Mr. Jerome D. Jabbour J.D.Co-Founder, Chairman, CEO, President & Interim CFO · b. 1974

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0194.49K0149.69K119.75K89.81K158.33K33.00K3.19M1.10M00
Growth (%)-----100.00%--20.00%-25.00%+76.29%-79.16%+9560.61%-65.62%-100.00%-
Cost of Revenue--5.18M5.29M52.64K9.01M6.79M11.23M14.36M14.58M16.68M941.00K972.00K456.00K
Gross Profit---5.18M-5.10M-52.64K-8.86M-6.67M-11.14M-14.20M-14.55M-13.49M155.00K-972.00K-456.00K
Gross Margin----2621.01%--5919.56%-5568.04%-12408.96%-8968.81%-44090.91%-423.15%14.14%--
Operating Expense--5.29M4.81M8.20M7.64M7.98M7.78M10.01M10.19M11.10M23.92M19.19M6.50M
Operating Income-116.08K-3.71M-10.46M-9.91M-8.26M-16.50M-14.65M-18.92M-24.21M-24.73M-24.59M-23.77M-20.16M-6.96M
Operating Margin----5096.04%--11024.61%-12230.94%-21067.38%-15288.38%-74954.55%-771.33%-2168.43%--
EBITDA--3.71M-10.42M-9.87M-8.20M-16.40M-14.43M-18.59M-23.92M-23.00M-20.64M-22.00M-19.19M-9.89M
EBITDA Margin----5073.68%--10957.40%-12048.63%-20701.32%-15105.21%-69706.06%-647.46%-2007.39%--
Net Income-116.08K-3.71M-10.22M-9.14M-7.60M-15.49M-14.08M-17.37M-22.45M-23.28M-21.00M-22.94M-24.25M-10.35M
Net Income Margin----4697.01%--10345.91%-11760.39%-19343.35%-14176.98%-70554.55%-658.63%-2093.25%--
R&D78.85K1.76M5.18M5.29M3.95M9.01M6.79M11.23M14.36M14.58M16.68M14.49M11.43M85.00K
R&D as % of Total Revenue---2721.01%-6019.56%5668.04%12508.96%9068.81%44190.91%523.15%1321.99%--
Interest Expense-000000001.45M3.59M---
Interest Expense % of Total Revenue---0.00%-0.00%0.00%0.00%0.00%4398.00%112.70%---

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets424.36K11.33M3.36M8.41M9.82M14.42M19.94M40.24M70.97M61.33M78.87M25.10M12.64M7.21M
Total Liabilities84.43K858.97K1.13M2.33M2.67M3.74M3.80M7.19M7.24M8.83M42.23M5.86M5.05M2.38M
Total Equity339.94K10.47M2.23M6.07M7.15M10.68M16.14M33.05M63.73M52.49M36.64M19.25M7.59M4.83M
Cash424.36K10.84M2.59M3.23M4.11M7.31M12.45M22.17M12.43M21.03M6.88M4.79M7.28M4.00M
Total Debt--59.65K11.26K144.43K264.89K390.75K4.23M3.75M4.70M4.12M3.56M2.89M1.35M
Net Debt-424.36K-10.84M-2.53M-3.22M-3.96M-7.04M-12.06M-17.94M-8.68M-16.33M-2.76M-1.23M-4.39M-2.65M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-57.26K-2.99M-7.96M-7.81M-6.12M-11.46M-10.32M-14.09M-17.37M-15.22M-19.16M-15.28M-15.88M-7.01M
Investing Cash Flow--94.19K-288.52K-5.42K-942.18K-942.18K-535.92K-6.01M-40.67M16.77M4.88M13.24M9.21M335.00K
Financing Cash Flow479.63K13.50M8.46M8.46M7.00M15.60M15.87M29.85M48.05M6.96M79.00K-7.00K9.17M3.39M
Capital Expenditure094.19K288.52K76.18K942.18K942.18K535.92K405.60K5.75K260.38K892.00K218.00K00
Free Cash Flow-57.26K-3.08M-8.25M-7.89M-6.12M-12.40M-10.86M-14.50M-17.37M-15.48M-20.05M-15.50M-15.88M-7.01M
Dividends Paid----4.39B608.34M587.14M2.23B682.80M843.60M----
FCF to OCF100.00%103.15%103.62%100.97%100.00%108.22%105.19%102.88%100.03%101.71%104.66%101.43%100.00%100.00%
Dividend Paid to FCF-----71809.25%-4905.35%-5407.91%-15412.34%-3930.10%-5448.26%----

Earnings

Report DateSep 3, 2014Nov 14, 2014Mar 31, 2015May 15, 2015Aug 13, 2015Nov 10, 2015Mar 30, 2016May 13, 2016Aug 15, 2016Nov 14, 2016Mar 31, 2017May 15, 2017Aug 8, 2017Nov 14, 2017Mar 16, 2018May 9, 2018Aug 9, 2018Nov 9, 2018Dec 31, 2018May 13, 2019Aug 13, 2019Nov 13, 2019Mar 9, 2020May 11, 2020Aug 10, 2020Nov 6, 2020Mar 29, 2021May 10, 2021Aug 10, 2021Nov 8, 2021Mar 8, 2022May 12, 2022Aug 11, 2022Nov 2, 2022Mar 15, 2023May 10, 2023Aug 9, 2023Nov 8, 2023Jan 9, 2024May 9, 2024Aug 14, 2024Nov 13, 2024Mar 25, 2025May 15, 2025Aug 13, 2025Nov 10, 2025Mar 26, 2026May 8, 2026Aug 13, 2026Nov 9, 2026
EPS Estimate--3.50--4.00-2.50-2.50-3.00---1.50-0.08-1.75-2.33-2.33-0.04-2.00-2.00-2.00-0.03-1.50-2.00-2.00-1.83-0.03-1.50-1.67-0.03-1.50-1.75-1.50-0.03-1.25-1.50-1.50-0.03-1.50-1.50-1.50-0.03-1.50-1.00-1.05-0.78-0.78------
EPS Actual-3.79-4.00-0.09-3.50-2.00-2.00-1.50-0.04-0.03-5.50-0.03-12.50-2.00-2.00-0.04-2.50-2.00-1.50-0.03-2.00-1.60-1.50-1.83-0.03-1.50-1.50-0.03-1.50-1.00-1.50-0.03-1.50-1.50-1.50-0.02-1.50-1.50-1.50-0.02-1.50-0.02-0.85-0.81-0.33-1.03-0.40-0.30-0.30-0.21-
Surprise--14.29%-12.50%20.00%20.00%50.00%---266.67%62.50%-614.29%14.16%14.16%0.00%-25.00%0.00%25.00%0.00%-33.33%20.00%25.00%0.00%0.00%0.00%10.18%0.00%0.00%42.86%0.00%0.00%-20.00%0.00%0.00%33.33%0.00%0.00%0.00%33.33%0.00%98.00%19.05%-3.28%57.69%------
Timing-After-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hours-----

Key Statistics & Ratios

Market Cap156.72K
Enterprise Value1.82M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales34.81
Price / Book1.43
EPS-1.15
Book Value0.281
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-6.66M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-141.24%
Return on Assets-56.17%
Shares Outstanding979.52K
Shares Float11.45M
Beta1.70
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 2 analystsTarget 30.00
  • Hold
    2